Medtronic Annoucnes New Data from Global SYMPLICITY Registry Affirm Strong Safety Profile

Medtronic, Inc.

, announced today at the European Society of Cardiology (ESC) Congress, new data from the Global SYMPLICITY Registry that continue to affirm the strong safety profile of the Symplicity(TM) renal denervation system in a real-world patient population. Among the 1,158 patients analyzed in the registry with follow-up information available for this analysis, major complications or serious adverse events related to delivery of radio frequency (RF) energy to the renal artery were rare, including one procedural dissection (0.09 percent) and one re-intervention at 6 months (0.09 percent). The primary goal of the Global SYMPLICITY Registry is to confirm procedural safety with the Symplicity system. Available data for the secondary efficacy analysis showed significant and sustained blood pressure reductions after renal denervation with the Symplicity system at all time points up to 12 months in both in-office and ambulatory blood pressure measurement, compared to baseline. The Symplicity renal denervation system is available for investigational use only in the United States. "It is encouraging that preliminary data with